U.S., April 4 -- ClinicalTrials.gov registry received information related to the study (NCT07510100) titled 'Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma' on March 10.
Brief Summary: This study is a single-armed, open-label, multicenter Phase 1/2 study to evaluate the efficacy and safety of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Equecabtagene Autoleucel) in subjects with relapsed and refractory Multiple Myeloma.
Study Start Date: May 10
Study Type: INTERVENTIONAL
Condition:
Relapsed/Refractory Multiple Myeloma
Intervention:
DRUG: Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Eque-cel)
Eque-cel consists of autologous T lymphocytes transduce...